Application of zingiberone in preparation of products for regulating biological lipid metabolism

Abstract

The invention discloses an application of zingerone in preparation of a product for regulating biological lipid metabolism, and finds that zingerone can effectively inhibit weight gain and hyperlipidemia caused by lipid metabolism disorder and effectively reduce the weight increment of white adipose tissues after peritoneum and the adipocyte area for the first time. The liver weight, the liver cell area and the lipid droplet content are obviously reduced, and the liver function is improved. Meanwhile, zingiberone is an effective component extracted from a natural plant ginger, so that zingiberone serving as a lipid metabolism regulating product has relatively good safety. The invention not only provides a new application of zingerone, but also provides a new therapeutic drug or health care product for preventing and treating obesity.

Description

Technical Field

[0001] The present invention belongs to the technical field of biological agents, and particularly relates to the application of zingerone in the preparation of products for regulating biological lipid metabolism. Background Art

[0002] With the improvement of people's living standards, there have been great changes in lifestyle compared with the past. High-calorie foods and excessive nutrition are ingested by the human body, coupled with insufficient exercise, resulting in the occurrence of obesity. Obesity has many harms. Obesity can cause high blood lipid, and excessive blood lipid will cause blood vessel stenosis and blockage. Obesity can also cause high blood pressure, and in severe cases, it can cause coronary heart disease and cerebrovascular diseases, seriously endangering people's physical health. Obesity can also cause metabolic disorders, such as metabolic diseases like diabetes. In addition, obesity can cause various psychological diseases, such as social phobia, and in severe cases, it can also affect fertility. Therefore, preventing and treating obesity is of great significance to both humans and animals.

[0003] Drugs for promoting fat metabolism are generally orlistat capsules and Qingshen Xiaopang Pills, etc. However, chemical drugs are accompanied by certain adverse effects and there is a problem of easy rebound after stopping the drug. For example, a large amount of use of statin drugs can cause liver and kidney function damage, necrotizing diseases and rhabdomyolysis. Therefore, it is necessary to seek other drugs that have a promoting effect on lipid metabolism.

[0004] In recent years, traditional Chinese medicine has shown remarkable effects in the research of preventing dyslipidemia. It has the advantages of regulating dyslipidemia through multiple pathways, multiple targets and multiple levels, can be used in multiple combinations, and can simultaneously achieve the effects of reducing blood lipid, antioxidant, reducing blood sugar, etc. Moreover, it has fewer adverse reactions and high safety, and has high clinical application value in the treatment of dyslipidemia. Summary of the Invention

[0005] Object of the Invention: The technical problem to be solved by the present invention is to provide the application of the active ingredient of ginger, zingerone, in the preparation of products for regulating biological lipid metabolism in view of the deficiencies of the prior art.

[0006] In order to achieve the above object, the technical solution adopted by the present invention is as follows: The application of zingerone in the preparation of products for regulating biological lipid metabolism.

[0007] Specifically, the zingerone described in the present invention can be a synthetic zingerone compound or a zingerone component extracted from ginger.

[0008] Specifically, the "biology" described in the present invention specifically refers to humans or animals.

[0009] Furthermore, the product can be animal feed.

[0010] Furthermore, the product can also be an animal feed additive.

[0011] Preferably, the addition amount of the zingerone as an animal feed additive in the feed is 0.1-0.5 wt%.

[0012] Furthermore, the product can be a drug for controlling the weight of humans / animals.

[0013] Furthermore, the product can also be a health care product for controlling the weight of humans.

[0014] Specifically, the present invention discovers for the first time that the zingerone can reduce triglycerides in biological serum.

[0015] Specifically, the present invention discovers for the first time that the zingerone can reduce the fat mass and fat coefficient of the epididymis of organisms.

[0016] Furthermore, the present invention also claims to protect the application of zingerone in the preparation of drugs for preventing and treating lipid metabolism disorder diseases of humans or animals.

[0017] Preferably, the zingerone described in the present invention is a natural zingerone component extracted from ginger.

[0018] Compared with the prior art, the present invention has the following beneficial effects: The present invention discovers that zingerone can effectively inhibit weight gain and hyperlipidemia caused by lipid metabolism disorder, effectively reduce the weight gain amount and adipocyte area of retroperitoneal white adipose tissue, significantly reduce liver weight, hepatocyte area and lipid droplet content, and improve liver function. At the same time, zingerone is an effective component extracted from the natural plant ginger. Therefore, as a product for regulating lipid metabolism, it has good safety. The present invention not only provides a new application of zingerone, but also provides a new therapeutic drug or health care product for the prevention and treatment of obesity. Brief Description of the Drawings

[0019] The following further specifically describes the present invention in conjunction with the drawings and specific embodiments, and the above and / or other advantages of the present invention will become clearer.

[0020] Figure 1 It is a comparison chart of the weight gain of two groups of mice in Example 2.

[0021] Figure 2 It is a comparison of the daily food intake of two groups of mice in Example 2.

[0022] Figure 3 It is a photo of HE staining of epididymal fat sections of two groups of mice in Example 4.

[0023] Figure 4 It is a photo of HE staining of liver tissue sections of two groups of mice in Example 4.

[0024] Figure 5 These are the Oil Red O staining photographs of the liver tissue sections of two groups of mice in Example 4. Detailed implementation manners

[0025] The present invention can be better understood according to the following examples.

[0026] Example 1 Preparation of zingerone mixed feed 1) Crush the SPF maintenance mouse feed (purchased from Qinglongshan Animal Breeding Farm) with a small feed crusher, about 300 g. 2) Accurately weigh 0.72 g of zingerone (purchased from MACKLIN Company, with a content of 98%) and grind it in a mortar. 3) Weigh 5 g of the crushed feed in step 1) and add it to step 2), and stir evenly. 4) Repeat step 3) once. 5) Weigh 10 g of the crushed feed in step 1) and add it to step 4), and stir evenly. 6) Repeat step 5) once. 7) Weigh 20 g of the crushed feed in step 1) and add it to step 6), and stir evenly. 8) Repeat step 7). 9) By analogy, add the crushed feed and stir evenly until the total amount is 300 g. 10) Add an appropriate amount of pure water to moisten the crushed feed, knead it forcefully by hand to form a long strip, place it on a newspaper, and air-dry it in a cool place at room temperature to obtain the zingerone mixed feed.

[0027] Example 2 Effects of zingerone on ob / ob body weight and fat coefficient of mice 1. Experimental animals Obese model mice ob / ob Mice, 4 weeks old, male, 10 in number, purchased from Jiangsu Jicui Yakang Biotechnology Co., Ltd.

[0028] 2. Animal grouping and medication ob / ob After 10 mice were adaptively fed for one week, they were randomly divided into two groups, with 5 mice in the medication group and 5 mice in the control group. The medication group was fed with the self-made zingerone mixed feed in Example 1, and the control group was fed with the standard maintenance feed for mice, with normal drinking water, and fed for 9 weeks.

[0029] During the experiment, the weight of the feed eaten by the mice was weighed every 3 - 4 days, the intake was calculated, and the daily feed intake of each mouse was calculated. The body weight of the mice was measured every two weeks, and the weekly average weight gain of the mice was calculated.

[0030] After the experiment, the mice were sacrificed by cervical dislocation, and the epididymal fat was weighed to calculate the fat coefficient. The fat coefficient = epididymal fat weight (g) / body weight (g) × 100%.

[0031] 3. Experimental Results According to Table 1 and Figure 1 it can be seen that the average weight gain of the mice in the medicated group for 9 consecutive weeks was significantly lower than that of the control group, indicating that zingerone has an inhibitory effect on the weight gain of mice.

[0032] Table 1 Effects of Zingerone on the Weight Gain of Mice

[0033] * Indicates a significant difference compared with the control group ( P < 0.05); ** Indicates a highly significant difference compared with the control group ( P < 0.01).

[0034] According to Figure 2 it can be seen that after feeding for 9 weeks, there was no difference (ns) in the average daily feed intake between the control group and the medicated group, indicating that zingerone has no effect on the feed intake of mice.

[0035] According to Table 2, after continuous administration for 9 weeks, both the epididymal fat mass and fat coefficient of the mice in the medicated group were significantly lower than those of the control group, indicating that zingerone has a promoting effect on lipid metabolism in mice.

[0036] Table 2 Effects of Zingerone on the Epididymal Fat Mass of Mice

[0037] * Indicates a significant difference compared with the control group ( P < 0.05).

[0038] Example 3 Results of the Effects of Zingerone on ob / ob the Serum Biochemical Indexes of Mice After the experiment in Example 2 ended, the eyeballs of the mice were removed to collect blood, the serum was separated, and the levels of triglyceride (TG), total cholesterol (CHO), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) in the mouse serum were detected using an automatic biochemical analyzer (Thermo Indiko).

[0039] As can be seen from Table 3, the content of triglyceride in the serum of the mice in the medicated group was extremely significantly lower than that of the control group, indicating that zingerone has a reducing effect on the content of triglyceride in the mice. There was no significant difference in the contents of CHO, LDL, and HDL in the serum of the mice in the medicated group and the control group.

[0040] Table 3 Results of the Effects of Zingerone on ob / ob the Serum Biochemical Indexes of Mice

[0041] ** Indicates a highly significant difference compared with the control group ( P < 0.01).

[0042] Example 4 Effects of zingerone on ob / ob histopathology of adipose and liver tissues of mice After the experiment in Example 2 was completed, the epididymal adipose and liver tissues of the mice were placed in 10% formalin for fixation for more than 24 h, dehydrated and then paraffin-embedded, sectioned, and placed in an automatic stainer for HE staining. After HE staining was completed, neutral resin was used for mounting. For the mouse liver tissue, it was fixed with formaldehyde-calcium solution, cryo-embedded with an embedding agent, and the liver tissue was cut into 10-μm thick frozen sections with a cryostat microtome and stained with Oil Red O staining solution. The steps were as follows: After the sections were dried, they were washed with 50% ethanol; the Oil Red O ethanol staining solution was allowed to act for 8 minutes; then differentiation was carried out with 50% ethanol, and after differentiation was completed, it was terminated with tap water; finally, the nuclei were counterstained with hematoxylin, blued with tap water, and mounted with glycerin jelly. The sections were placed under an optical microscope to observe the tissue morphology. The size of epididymal fat cells and the number and size of lipid droplets in hepatocytes of liver tissue were observed under the optical microscope, and the area (μm²) of fat cells was measured with Image J software, and the average area was calculated and inter-group analysis was performed.

[0043] From Figure 3 and Table 4, it can be seen that the size of fat cells in the medicated group was significantly smaller than that in the control group, and the average area of epididymal fat cells in the medicated group of mice was significantly smaller than that of epididymal fat cells in the control group of mice.

[0044] Table 4 Effects of zingerone on the area of epididymal fat cells in mice

[0045] * Indicates a significant difference compared with the control group ( P < 0.05).

[0046] By microscopic examination of the HE-stained sections ( Figure 4 ) and Oil Red O-stained sections ( Figure 5 ) of the liver tissue, it can be seen that the number of hepatocytes with fatty degeneration in the liver tissue of the control group of mice was significantly more than that in the medicated group of mice, and the number of their lipid droplets was significantly more than that of the medicated group of mice. It shows that zingerone has a reducing effect on fatty degeneration of hepatocytes in the liver tissue of mice and the number of lipid droplets therein.

[0047] In summary, the zingerone mixed feed prepared by the present invention can significantly reduce ob / obThe weight gain of obese model mice was reduced, the epididymal fat mass and fat coefficient were decreased, the serum triglyceride level of mice was significantly reduced, the average area of epididymal fat cells was significantly reduced, the number of lipid droplets in hepatocytes was significantly decreased, and hepatic steatosis was alleviated. This provides a new direction for the application of zingerone and also a new source for developing drug regimens / dietary therapies for preventing and treating obesity.

[0048] The present invention provides an idea and method for the application of zingerone in the preparation of products for regulating biological lipid metabolism. There are many methods and ways to specifically implement this technical solution. The above is only the preferred embodiment of the present invention. It should be noted that for those of ordinary skill in the art, without departing from the principle of the present invention, several improvements and refinements can be made, and these improvements and refinements should also be regarded as the protection scope of the present invention. Each component not clearly defined in this embodiment can be realized by existing technologies.

Claims

1. Application of zingerone in the preparation of products for regulating biological lipid metabolism.

2. The application according to claim 1, wherein The biological being is human or animal.

3. The application according to claim 1, characterized in that, The product is an animal feed additive.

4. The application according to claim 4, characterized in that, The addition amount of zingerone as an animal feed additive in the feed is 0.1 - 0.5 wt%.

5. The application according to claim 1, wherein The product is a medicine for controlling the weight of human or animal.

6. The application according to claim 1, characterized in that, The product is a health product for controlling human weight.

7. The application according to claim 1, characterized in that, The zingerone can reduce triglyceride in biological serum.

8. The application according to claim 1, wherein The zingerone can reduce the fat mass and fat coefficient of biological epididymis.

9. Application of zingerone in the preparation of drugs for preventing and treating lipid metabolism disorder diseases of human or animal.

10. The application according to claim 9, wherein, The zingerone is natural zingerone extracted from ginger.

Images